Personalized precision radiotherapy and its evolving role for human papillomavirus-positive oropharyngeal cancer

Mehta, 2010, Population-based analysis of oral and oropharyngeal carcinoma: changing trends of histopathologic differentiation, survival and patient demographics, Laryngoscope, 120, 2203, 10.1002/lary.21129 Sturgis, 2007, Trends in head and neck cancer incidence in relation to smoking prevalence, Cancer, 110, 1429, 10.1002/cncr.22963 Pan, 2018, HPV-driven oropharyngeal cancer: current knowledge of molecular biology and mechanisms of carcinogenesis, Cancers Head Neck, 3, 12, 10.1186/s41199-018-0039-3 Pytynia, 2014, Epidemiology of HPV-associated oropharyngeal cancer, Oral Oncol, 50, 380, 10.1016/j.oraloncology.2013.12.019 Gillison, 2015, Epidemiology of human papillomavirus–positive head and neck squamous cell carcinoma, J Clin Oncol, 33, 3235, 10.1200/JCO.2015.61.6995 Gillison, 2012, Prevalence of Oral HPV infection in the United States, 2009-2010, JAMA, 307, 693, 10.1001/jama.2012.101 D'Souza, 2009, Oral sexual behaviors associated with prevalent oral human papillomavirus infection, J Infect Dis, 199, 1263, 10.1086/597755 Giuliano, 2014, EUROGIN 2014 roadmap: differences in human papillomavirus infection natural history, transmission and human papillomavirus-related cancer incidence by gender and anatomic site of infection, Int J Cancer, 136, 2752, 10.1002/ijc.29082 Kjaer, 2001, High-risk human papillomavirus is sexually transmitted: evidence from a follow-up study of virgins starting sexual activity (intercourse), Cancer Epidemiol Biomarkers Prev, 10, 101 Cmelak, 2007, Phase II trial of chemoradiation for organ preservation in resectable stage III or IV squamous cell carcinomas of the larynx or oropharynx: results of Eastern Cooperative Oncology Group Study E2399, J Clin Oncol, 25, 3971, 10.1200/JCO.2007.10.8951 Fakhry, 2008, Improved survival of patients with human papillomavirus-positive head and neck squamous cell carcinoma in a prospective clinical trial, J Natl Cancer Inst, 100, 261, 10.1093/jnci/djn011 Gillison, 2009, Survival outcomes by tumor human papillomavirus (HPV) status in stage III-IV oropharyngeal cancer (OPC) in RTOG 0129, J Clin Oncol, 27, 6003, 10.1200/jco.2009.27.15_suppl.6003 Ang, 2010, Human papillomavirus and survival of patients with oropharyngeal cancer, N Engl J Med, 363, 24, 10.1056/NEJMoa0912217 Nguyen-Tan, 2014, Randomized phase III trial to test accelerated versus standard fractionation in combination with concurrent cisplatin for head and neck carcinomas in the Radiation Therapy Oncology Group 0129 trial: long-term report of efficacy and toxicity, J Clin Oncol, 32, 3858, 10.1200/JCO.2014.55.3925 Fakhry, 2014, Human papillomavirus and overall survival after progression of oropharyngeal squamous cell carcinoma, J Clin Oncol, 32, 3365, 10.1200/JCO.2014.55.1937 Bucci, 2005, Advances in radiation therapy: conventional to 3D, to IMRT, to 4D, and beyond, CA Cancer J Clin, 55, 117, 10.3322/canjclin.55.2.117 2001, Intensity-modulated radiotherapy: current status and issues of interest, Int J Radiat Oncol Biol Phys, 51, 880, 10.1016/S0360-3016(01)01749-7 Grégoire, 2007, Intensity-modulated radiation therapy for head and neck carcinoma, Oncologist, 12, 555, 10.1634/theoncologist.12-5-555 Boeke, 2021, MR-guided radiotherapy for head and neck cancer: current developments, perspectives, and challenges, Front Oncol, 11, 10.3389/fonc.2021.616156 Chuter, 2018, Assessing MR-linac radiotherapy robustness for anatomical changes in head and neck cancer, Phys Med Biol, 63, 10.1088/1361-6560/aac749 Gharzai, 2022, Magnetic resonance guided radiotherapy for head and neck cancers, J Clin Med, 11, 1388, 10.3390/jcm11051388 Kupelian, 2014, Magnetic resonance-guided adaptive radiotherapy: a solution to the future, Semin Radiat Oncol, 24, 227, 10.1016/j.semradonc.2014.02.013 Pollard, 2017, The future of image-guided radiotherapy will be MR guided, Br J Radiol, 90, 10.1259/bjr.20160667 Vandecaveye, 2007, Detection of head and neck squamous cell carcinoma with diffusion weighted MRI after (chemo)radiotherapy: correlation between radiologic and histopathologic findings, Int J Radiat Oncol Biol Phys, 67, 960, 10.1016/j.ijrobp.2006.09.020 Zhang, 2013, Diffusion-weighted MR imaging of salivary glands with gustatory stimulation: comparison before and after radiotherapy, Acta Radiol, 54, 928, 10.1177/0284185113491089 Chen, 2018, MRI-guided radiotherapy for head and neck cancer: initial clinical experience, Clin Transl Oncol, 20, 160, 10.1007/s12094-017-1704-4 Bahig, 2018, Clin Transl Radiat Oncol, 13, 19, 10.1016/j.ctro.2018.08.003 Balermpas P. MARTHA-trial: MRI - guided adaptive radiotherapy for reducing xerostomia in head and neck cancer including longitudinal evaluation of the patient's immune profile under radiotherapy. Clinicaltrialsgov. Published May 16, 2022. Accessed October 4, 2022. https://clinicaltrials.gov/ct2/show/NCT03972072 Royal Marsden NHS Foundation Trust. Optimising radiation therapy in head and neck cancers using functional image-guided radiotherapy and novel biomarkers. clinicaltrialsgov. Published July 21, 2021. Accessed October 4, 2022. https://clinicaltrials.gov/ct2/show/NCT04242459 Silver, 2022, De-escalation strategies for human papillomavirus-associated oropharyngeal squamous cell carcinoma-where are we now?, Curr Oncol, 29, 3668, 10.3390/curroncol29050295 Nutting, 2011, Parotid-sparing intensity modulated versus conventional radiotherapy in head and neck cancer (PARSPORT): a phase 3 multicentre randomised controlled trial, Lancet Oncol, 12, 127, 10.1016/S1470-2045(10)70290-4 Mendenhall, 2014, Submandibular gland-sparing intensity-modulated radiotherapy, Am J Clin Oncol, 37, 514, 10.1097/COC.0b013e318261054e Studer, 2006, Osteoradionecrosis of the mandible: minimized risk profile following intensity-modulated radiation therapy (IMRT), Strahlenther Onkol, 182, 283, 10.1007/s00066-006-1477-0 Gamez, 2021, Deintensification strategies using proton beam therapy for HPV-related oropharyngeal cancer, Int J Part Ther, 8, 223, 10.14338/IJPT-20-00073.1 Blanchard, 2016, Intensity-modulated proton beam therapy (IMPT) versus intensity-modulated photon therapy (IMRT) for patients with oropharynx cancer - a case matched analysis, Radiother Oncol, 120, 48, 10.1016/j.radonc.2016.05.022 Sio, 2016, Intensity modulated proton therapy versus intensity modulated photon radiation therapy for oropharyngeal cancer: first comparative results of patient-reported outcomes, Int J Radiat Oncol Biol Phys, 95, 1107, 10.1016/j.ijrobp.2016.02.044 Sharma, 2018, Quality of life of postoperative photon versus proton radiation therapy for oropharynx cancer, Int J Part Ther, 5, 11, 10.14338/IJPT-18-00032.1 Wright, 2021, Dosimetric results for adjuvant proton radiation therapy of HPV-associated oropharynx cancer, Int J Part Ther, 8, 47, 10.14338/IJPT-D-21-00018 M.D. Anderson Cancer Center, National Cancer Institute (NCI), National Institute of Dental and Craniofacial Research (NIDCR). Phase II/III randomized trial of intensity-modulated proton beam therapy (IMPT) versus intensity-modulated photon therapy (IMRT) for the treatment of oropharyngeal cancer of the head and neck. clinicaltrialsgov. Published May 13, 2022. Accessed October 4, 2022. https://www.clinicaltrials.gov/ct2/show/NCT01893307 Amsbaugh, 2016, Distribution of cervical lymph node metastases from squamous cell carcinoma of the oropharynx in the era of risk stratification using human papillomavirus and smoking status, Int J Radiat Oncol Biol Phys, 96, 349, 10.1016/j.ijrobp.2016.06.2450 Tirelli, 2022, Prevalence and prognostic impact of retropharyngeal lymph nodes metastases in oropharyngeal squamous cell carcinoma: meta-analysis of published literature, Head Neck, 44, 2265, 10.1002/hed.27166 Iyizoba-Ebozue, 2020, Incidence and patterns of retropharyngeal lymph node involvement in oropharyngeal carcinoma, Radiother Oncol, 142, 92, 10.1016/j.radonc.2019.07.021 Spector, 2016, Exploration for an algorithm for deintensification to exclude the retropharyngeal site from advanced oropharyngeal squamous cell carcinoma treatment, JAMA Otolaryngol Head Neck Surg, 142, 313, 10.1001/jamaoto.2015.3602 Bussels, 2006, Retropharyngeal nodes in squamous cell carcinoma of oropharynx: incidence, localization, and implications for target volume, Int J Radiat Oncol Biol Phys, 65, 733, 10.1016/j.ijrobp.2006.02.034 Sanguineti, 2009, Defining the risk of involvement for each neck nodal level in patients with early T-stage node-positive oropharyngeal carcinoma, Int J Radiat Oncol Biol Phys, 74, 1356, 10.1016/j.ijrobp.2008.10.018 Sanguineti, 2014, HPV-related oropharyngeal carcinoma with Overt Level II and/or III metastases at presentation: the risk of subclinical disease in ipsilateral levels IB, IV and V, Acta Oncol, 53, 662, 10.3109/0284186X.2013.858825 Spencer, 2014, Eliminating radiotherapy to the contralateral retropharyngeal and high level II lymph nodes in head and neck squamous cell carcinoma is safe and improves quality of life, Cancer, 120, 3994, 10.1002/cncr.28938 Kjems, 2016, Elective nodal irradiation and patterns of failure in head and neck cancer after primary radiation therapy, Int J Radiat Oncol Biol Phys, 94, 775, 10.1016/j.ijrobp.2015.12.380 O'Sullivan, 2001, The benefits and pitfalls of ipsilateral radiotherapy in carcinoma of the tonsillar region [published correction appears in Int J Radiat Oncol Biol Phys 2001 Dec 1;51(5):1465], Int J Radiat Oncol Biol Phys, 51, 332 Tsai, 2021, Ipsilateral radiation for squamous cell carcinoma of the tonsil: American radium society appropriate use criteria executive summary, Head Neck, 43, 392, 10.1002/hed.26492 National Cancer Institute (NCI), NRG oncology. a randomized phase II/III trial of de-intensified radiation therapy for patients with early-stage, p16-positive, non-smoking associated oropharyngeal cancer. clinicaltrialsgov. Published March 17, 2022. https://clinicaltrials.gov/ct2/show/NCT03952585 Bauwens, 2021, Prevalence and distribution of cervical lymph node metastases in HPV-positive and HPV-negative oropharyngeal squamous cell carcinoma, Radiother Oncol, 157, 122, 10.1016/j.radonc.2021.01.028 Tsai, 2022, Evaluation of substantial reduction in elective radiotherapy dose and field in patients with human papillomavirus-associated oropharyngeal carcinoma treated with definitive chemoradiotherapy, JAMA Oncol, 8, 364, 10.1001/jamaoncol.2021.6416 Seiwert, 2019, OPTIMA: a phase II dose and volume de-escalation trial for human papillomavirus-positive oropharyngeal cancer [published correction appears in Ann Oncol. 2019 Oct 1;30(10):1673], Ann Oncol, 30, 297, 10.1093/annonc/mdy522 Sher, 2021, Prospective phase 2 study of radiation therapy dose and volume de-escalation for elective neck treatment of oropharyngeal and laryngeal cancer, Int J Radiat Oncol Biol Phys, 109, 932, 10.1016/j.ijrobp.2020.09.063 Yom, 2021, Reduced-dose radiation therapy for HPV-associated oropharyngeal carcinoma (NRG Oncology HN002), J Clin Oncol, 39, 956, 10.1200/JCO.20.03128 Caudell, 2022, NCCN guidelines® insights: head and neck cancers, version 1.2022, J Natl Compr Canc Netw, 20, 224, 10.6004/jnccn.2022.0016 Dagan, 2021, Radiation treatment deintensification for HPV-associated oropharyngeal cancer, Semin Radiat Oncol, 31, 324, 10.1016/j.semradonc.2021.02.010 Nichols, 2019, Radiotherapy versus transoral robotic surgery and neck dissection for oropharyngeal squamous cell carcinoma (ORATOR): an open-label, phase 2, randomised trial [published correction appears in Lancet Oncol. 2019 Dec;20(12):e663], Lancet Oncol, 20, 1349, 10.1016/S1470-2045(19)30410-3 Nichols, 2022, Randomized trial of radiotherapy versus transoral robotic surgery for oropharyngeal squamous cell carcinoma: long-term results of the ORATOR trial, J Clin Oncol, 40, 866, 10.1200/JCO.21.01961 Palma, 2022, Assessment of toxic effects and survival in treatment deescalation with radiotherapy vs transoral surgery for HPV-associated oropharyngeal squamous cell carcinoma: the ORATOR2 phase 2 randomized clinical trial, JAMA Oncol, 8, 1, 10.1001/jamaoncol.2022.0615 Ferris, 2022, Phase II randomized trial of transoral surgery and low-dose intensity modulated radiation therapy in resectable p16+ locally advanced oropharynx cancer: an ECOG-ACRIN cancer research group trial (E3311), J Clin Oncol, 40, 138, 10.1200/JCO.21.01752 Ma, 2019, Phase II evaluation of aggressive dose de-escalation for adjuvant chemoradiotherapy in human papillomavirus-associated oropharynx squamous cell carcinoma [published correction appears, J Clin Oncol, 37, 1909, 10.1200/JCO.19.00463 Ma, 2021, MC1675, a phase III evaluation of de-escalated adjuvant radiation therapy (DART) vs. standard adjuvant treatment for human papillomavirus associated oropharyngeal squamous cell carcinoma, Int J Radiat Oncol Biol Phys, 111, 1324, 10.1016/j.ijrobp.2021.09.012 Swisher-McClure, 2020, A phase 2 trial of alternative volumes of oropharyngeal irradiation for de-intensification (AVOID): omission of the resected primary tumor bed after transoral robotic surgery for human papilloma virus-related squamous cell carcinoma of the oropharynx, Int J Radiat Oncol Biol Phys, 106, 725, 10.1016/j.ijrobp.2019.11.021 Dhere, 2022, The omission of intentional primary site radiation following transoral robotic surgery in 59 patients: no local-regional failures, Head Neck, 44, 382, 10.1002/hed.26928 O'Sullivan, 2013, Deintensification candidate subgroups in human papillomavirus-related oropharyngeal cancer according to minimal risk of distant metastasis, J Clin Oncol, 31, 543, 10.1200/JCO.2012.44.0164 Anderson, 2019, De-escalation strategies in HPV-associated oropharynx cancer-are we putting the cart before the horse?, Int J Radiat Oncol Biol Phys, 104, 705, 10.1016/j.ijrobp.2019.02.054 Bonner, 2006, Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and neck, N Engl J Med, 354, 567, 10.1056/NEJMoa053422 Ang, 2014, Randomized phase III trial of concurrent accelerated radiation plus cisplatin with or without cetuximab for stage III to IV head and neck carcinoma: RTOG 0522, J Clin Oncol, 32, 2940, 10.1200/JCO.2013.53.5633 Gillison, 2019, Radiotherapy plus cetuximab or cisplatin in human papillomavirus-positive oropharyngeal cancer (NRG Oncology RTOG 1016): a randomised, multicentre, non-inferiority trial [published correction appears in Lancet. 2020 Mar 7;395(10226):784], Lancet, 393, 40, 10.1016/S0140-6736(18)32779-X Mehanna, 2019, Radiotherapy plus cisplatin or cetuximab in low-risk human papillomavirus-positive oropharyngeal cancer (De-ESCALaTE HPV): an open-label randomised controlled phase 3 trial, Lancet, 393, 51, 10.1016/S0140-6736(18)32752-1 Gebre-Medhin, 2021, ARTSCAN III: a randomized phase III study comparing chemoradiotherapy with cisplatin versus cetuximab in patients with locoregionally advanced head and neck squamous cell cancer, J Clin Oncol, 39, 38, 10.1200/JCO.20.02072 Chera, 2015, Phase 2 trial of de-intensified chemoradiation therapy for favorable-risk human papillomavirus-associated oropharyngeal squamous cell carcinoma, Int J Radiat Oncol Biol Phys, 93, 976, 10.1016/j.ijrobp.2015.08.033 Chera, 2019, Phase II trial of De-intensified chemoradiotherapy for human papillomavirus-associated oropharyngeal squamous cell carcinoma, J Clin Oncol, 37, 2661, 10.1200/JCO.19.01007 Mell, 2021, Phase II Randomized Trial of Radiotherapy With Concurrent and Adjuvant Pembrolizumab (Keytruda®) Versus Concurrent Chemotherapy in Patients With Advanced/Intermediate-Risk p16+ Head and Neck Squamous Cell Carcinoma (KEYCHAIN), clinicaltrials.gov Piotrowski, 2021, miRNAs as biomarkers for diagnosing and predicting survival of head and neck squamous cell carcinoma patients, Cancers, 13, 3980, 10.3390/cancers13163980 Golusinski, 2021, De-escalation studies in HPV-positive oropharyngeal cancer: how should we proceed?, Oral Oncol, 123, 10.1016/j.oraloncology.2021.105620 Campo, 2022, Cell-free human papillomavirus-DNA for monitoring treatment response of head and neck squamous cell carcinoma: systematic review and meta-analysis, Laryngoscope, 132, 560, 10.1002/lary.29739 Hanna, 2018, Plasma HPV cell-free DNA monitoring in advanced HPV-associated oropharyngeal cancer, Ann Oncol, 29, 1980, 10.1093/annonc/mdy251 Chera, 2019, Rapid clearance profile of plasma circulating tumor HPV Type 16 DNA during chemoradiotherapy correlates with disease control in HPV-associated oropharyngeal cancer, Clin Cancer Res, 25, 4682, 10.1158/1078-0432.CCR-19-0211 Chera, 2020, Plasma circulating tumor HPV DNA for the surveillance of cancer recurrence in HPV-associated oropharyngeal cancer [published correction appears in J Clin Oncol. 2020 Oct 20;38(30):3579], J Clin Oncol, 38, 1050, 10.1200/JCO.19.02444 Rutkowski, 2020, Circulating HPV16 DNA may complement imaging assessment of early treatment efficacy in patients with HPV-positive oropharyngeal cancer, J Transl Med, 18, 167, 10.1186/s12967-020-02330-y Corredor, 2019, Spatial architecture and arrangement of tumor-infiltrating lymphocytes for predicting likelihood of recurrence in early-stage non-small cell lung cancer, Clin Cancer Res, 25, 1526, 10.1158/1078-0432.CCR-18-2013 Azarianpour Esfahani, 2020, Computerized features of spatial arrangement of tumor-infiltrating lymphocytes from H&E images predicts survival and response to checkpoint inhibitors in gynecologic cancers, J Clin Oncol, 38, 6074, 10.1200/JCO.2020.38.15_suppl.6074 Corredor, 2022, An imaging biomarker of tumor-infiltrating lymphocytes to risk-stratify patients with HPV-associated oropharyngeal cancer, J Natl Cancer Inst, 114, 609, 10.1093/jnci/djab215 Morand, 2022, Molecular prognostic indicators in HPV-positive oropharyngeal cancer: an updated review, Clin Exp Metastasis, 39, 407, 10.1007/s10585-022-10148-9 Rietbergen, 2014, Cancer stem cell enrichment marker CD98: a prognostic factor for survival in patients with human papillomavirus-positive oropharyngeal cancer, Eur J Cancer, 50, 765, 10.1016/j.ejca.2013.11.010 Kano, 2019, Expression of estrogen receptor alpha is associated with pathogenesis and prognosis of human papillomavirus-positive oropharyngeal cancer, Int J Cancer, 145, 1547, 10.1002/ijc.32500 Rosenberg, 2021, Optimizing treatment De-escalation in head and neck cancer: current and future perspectives, Oncologist, 26, 40, 10.1634/theoncologist.2020-0303